Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.